www.youtube.com/watch?v=YATNd-cq4A4

Continued here:
Greenway Medical Technologies celebrates IPO and rings the NYSE Opening Bell – Video

www.youtube.com/watch?v=Wm-YXQrbSpc

Originally posted here:
Alien Knowledge in Ancient Egypt: Pineal Gland, Chakras – Video

See the rest here:
Who is in the news? Kevin Goodwin

www.youtube.com/watch?v=qd70mrH5uiI

More here:
Ophthalmic Medical Technology Profile – Video

TORONTO–(Marketwire – February 02, 2012) – SenoSENSE Medical Systems Inc., a medical device company engaged in the development of innovative technologies targeted to reducing the impact of breast cancer in younger women, announced today that it has received an Investigational Testing Approval (ITA) from Health Canada. Receipt of the ITA enables the company to initiate clinical testing of SenoSENSE's proprietary Densitrode technology which is planned to begin in February 2012 at Timmins and District Hospital. Dr. Karina Bukhanov, Breast Radiologist with Mount Sinai Hospital Marvelle Koffler Breast Centre and Gattuso Rapid Diagnosis Clinic at Princess Margaret Hospital is the principal investigator for the initial studies.

“The receipt of Investigation Testing Approval for the Densitrode(TM) beast density sensor represents the first important step in advancing an exciting new technology that we believe offers great promise to identify younger women who are at increased risk of breast cancer, enable proactive intervention to reduce their risk and initiate earlier surveillance to identify cancer at an earlier and more treatable stage,” commented Joel Ironstone, President and Chief Executive Officer of SenoSENSE Medical Systems.

About SenoSENSE Medical

SenoSENSE Medical Systems is a Toronto, Ontario-based early stage medical device company developing technology that enables personalized assessment of breast cancer risk in younger women. The company's first product, the Electrical Breast Densitometer, employs proprietary Densitrode technology to assess breast density in combination with other well-accepted breast cancer risk factors. Breast density has emerged as one of the most important determinants of breast cancer risk. A woman with high breast density has 4-6 times higher risk of developing breast cancer than a woman with fatty, low density tissue. Breast cancer is the most prevalent cause of death in women under the age of 50.

Originally posted here:
SenoSENSE Medical Receives Health Canada Investigational Testing Approval for Densitrode(TM) Technology

Go here to read the rest:
Nanostart-holding MagForce AG Announces Capital Increase from Authorized Capital

Excerpt from:
STENTYS concludes clinical trial ahead of plan

By Geoff Percival

Thursday, February 02, 2012

Ireland is being positioned as a global leader of the medical technology sector by 2015, with the industry set to be a “key driver” in the country’s ongoing export-led economic growth.

At the launch of its four-year strategy yesterday, the IBEC-affiliated Irish Medical Device Association said its aim is that, by 2015, Irish-made medical technology products and solutions will be major contributors to global healthcare and the global economy. It sees Ireland as an international location of choice for the industry due to its expertise and pro-business environment.

There are 250 medical technology companies operating in Ireland, 50% of which are indigenous firms. These companies employ around 25,000 people and export €7.2bn worth of products per year. Ireland is already ranked as the leader in terms of inward investment from the sector.

Incoming Irish Medical Device Association chairman Paraic Curtis said: “The industry is poised for rapid convergence between technologies, which will result in more collaboration and new products in drug device and smart device development.”

However, he said the next four years will not be without challenges — particularly with global healthcare expenditure coming under increasing pressure — but said “given the industry’s existing capacity to adapt, it’s in a strong position to address these challenges”.

IDA Ireland chief executive Barry O’Leary said: “Ireland is very much leading the field when it comes to medical technology. Seventeen of the world’s top 25 medical technology companies have invested significantly in Ireland and there is a pattern of indigenous companies emerging and competing internationally.”

Over the course of 2011, Irish-based medical technology companies announced investments of a combined €170m, leading to the creation of 875 jobs, which will come on stream in the coming years.

a d v e r t i s e m e n t

This appeared in the printed version of the Irish Examiner Thursday, February 02, 2012

Read the original post:
Ireland to be medical tech leader

SAN DIEGO, Feb. 2, 2012 /PRNewswire/ — CareFusion Corp. (NYSE: CFN – News), a leading, global medical technology company, today reported results for the three and six months ended Dec. 31, 2011.  

“Our second quarter results were led by strong performance across the Medical Systems segment, with our three major businesses achieving positive gains and positioning us well for the second half of the year,” said Kieran Gallahue, chairman and CEO. “These results were partially offset by our performance in the Procedural Solutions segment, as we indicated in our preliminary earnings report last month. We continue to believe that our highly differentiated Procedural Solutions products will grow faster than the market and remain meaningful contributors to our long-term performance.

“We continued to make good progress on our efforts to build our foundation and to invest in areas that will help simplify how we do business so we can expand margins and accelerate top-line growth over the long term. We remain committed to our long-term growth targets and are confident we will make progress against these goals this fiscal year.”

Second Quarter Results

The company reported revenue for the second quarter of fiscal 2012 of $915 million, compared to $886 million in the second quarter of fiscal 2011, an increase of 3 percent on a reported and constant currency basis.

Operating income was $143 million, an increase of 17 percent compared to $122 million in the prior year period. Excluding nonrecurring items, adjusted operating income for the second quarter was unchanged at $150 million.

Operating expenses totaled $314 million in the second quarter. Excluding nonrecurring items, adjusted operating expenses were $307 million, an increase of 4 percent over the prior year period, primarily driven by operating expenses from Rowa Technologies, which the company acquired in August 2011. In addition, the company increased investments in research and development during the quarter and benefited from ongoing cost-savings initiatives in the company's administrative support functions.

The company reported income from continuing operations in the second quarter of $95 million, or $0.42 per diluted share. Adjusted income from continuing operations increased 4 percent from the prior year period to $99 million, or $0.44 per diluted share. The adjusted tax rate was 25.2 percent for the second quarter.

Medical Systems

Second quarter revenue for the Medical Systems segment increased 9 percent from the prior year period on a reported and constant currency basis to $571 million, driven by strong sales across the segment. The company's Dispensing Technologies business, which grew in part from a contribution from the first-quarter acquisition of Rowa Technologies, also delivered its second strongest first-half organic revenue and committed contract performance in its history. The Infusion Systems business also achieved solid revenue growth, driven by installations of a record number of competitive channels during the quarter.

The revenue growth resulted in higher segment profit for the quarter, which increased 27 percent from the prior year period to $121 million. Adjusted segment profit increased 12 percent from the prior year period to $124 million.

Procedural Solutions

Second quarter revenue for the Procedural Solutions segment decreased 5 percent from the prior year period on a reported and constant currency basis. The decrease was driven, in part, by the loss of sales from divesting the company's OnSite Services business in March 2011. Net of the OnSite Services business divestiture, segment revenues decreased 2 percent from the prior year period. The segment results were also affected by decreased sales of respiratory disposables products in the Specialty Disposables business.

The revenue decline led to a decrease in segment profit of 19 percent from the prior year period to $22 million, and adjusted segment profit decreased 33 percent to $26 million.  

Six-Month Results

For the first six months of fiscal 2012, revenue increased 4 percent from the prior year period to $1.76 billion. Operating income increased to $251 million from $201 million in the prior year period. Income from continuing operations was $162 million, or $0.72 per diluted share. Adjusted income from continuing operations increased 10 percent from the prior year period to $175 million, or $0.78 per diluted share.

Operating expenses in the first six months totaled $633 million, or $615 million on an adjusted basis.  

Segment results for the six months ended Dec. 31, 2011 and 2010 are as follows:

Medical Systems

1H FY12

1H FY11

Y/Y

Revenue

$1,080 million

$991 million

9%

Segment Profit

$209 million

$163 million

28%

Adjusted Segment Profit

$219 million

$201 million

9%

Procedural Solutions

1H FY12

1H FY11

Y/Y

Revenue

$679 million

$706 million

(4)%

Segment Profit

$42 million

$38 million

11%

Adjusted Segment Profit

$50 million

$67 million

(25)%

Additional second quarter and recent highlights included:

Launching the Pyxis® Enterprise System (ES) platform, the next generation of CareFusion's industry-leading automated dispensing systems that will enable hospital customers to simplify and standardize the medication management process, both within a single facility and across an entire health system. Notable product releases on the platform are the Pyxis Enterprise Server, Pyxis MedStation® ES and CareFusion Coordination Engine. Launching the CareFusion Ventilation System, combining CareFusion's industry-leading ventilators with new interoperability and analytics software to better address clinical and operational challenges in patient care. Receiving federal data encryption certification for the Alaris® System, becoming the first and only infusion system to receive the National Institute of Standards and Technology certification now required for infusion devices operating on the U.S. Department of Veterans Affairs' hospital networks. Earning top rankings from KLAS, an independent market research firm that awarded MedMined® Services the No. 1 ranking in its 2011 annual report on infection control and monitoring providers, and from MD Buyline, which recognized Pyxis® technologies as number one in user satisfaction ratings in its December 2011 quarterly report. Launching the Nicolet™ EEG (Electroencephalography) Wireless Amplifier, a device that effectively captures high-resolution brain wave data to be used with the Nicolet Neurodiagnostic system.

Fiscal 2012 Outlook

CareFusion continues to expect full-year consolidated revenue to grow 3 to 5 percent on a constant currency basis compared to fiscal 2011 revenue of $3.53 billion. The company narrowed its previous full-year guidance range for adjusted diluted EPS from continuing operations of $1.75 to $1.90 to a new range of $1.75 to $1.85.

The guidance is based on an assumed diluted weighted average outstanding share count of approximately 227 million.

Conference Call

CareFusion will host a conference call today at 2 p.m. PST (5 p.m. EST) to discuss earnings results for the second quarter fiscal 2012.

To access the call and corresponding slide presentation, visit the Investors page at www.carefusion.com. Log on at least 15 minutes before the call begins to register and download or install any necessary audio software.

Investors and other interested parties may also access the call by dialing (800) 901-5247 within the U.S. or (617) 786-4501 from outside the U.S., and use the access code 28588340. A replay of the conference call will be available from 5 p.m. PST (8 p.m. EST) on Feb. 2 through 8:59 p.m. PST (11:59 p.m. EST) on Feb. 9 and can be accessed by dialing (888) 286-8010 in the U.S. or (617) 801-6888 internationally and using the access code 19918894.

About CareFusion Corporation

CareFusion (NYSE: CFN – News) is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. The company develops market-leading technologies including Alaris® infusion pumps, Pyxis® automated dispensing and patient identification systems, AVEA®, AirLife™ and LTV® series ventilation and respiratory products, ChloraPrep® products, MedMined® services for data mining surveillance, Nicolet™ neurological monitoring and diagnostic products, V. Mueller® surgical instruments, and an extensive line of products that support interventional medicine. CareFusion employs more than 14,000 people across its global operations. More information may be found at www.carefusion.com.

###

Use of Non-GAAP Financial Measures by CareFusion Corporation

This CareFusion news release presents non-GAAP financial measures that exclude certain amounts, as follows: “adjusted operating expenses” and “adjusted operating income”, which exclude nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges; “adjusted income from continuing operations”, “adjusted diluted earnings per share from continuing operations” and “adjusted tax rate”, which exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges and nonrecurring tax items; and “adjusted segment profit”, which excludes nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.

The most directly comparable measure for these non-GAAP financial measures are operating expenses, operating income, income from continuing operations, diluted earnings per share from continuing operations, tax rate, and segment profit (the most comparable GAAP measures). The company has included below unaudited adjusted financial information for the quarters and six months ended Dec. 31, 2011 and 2010, which includes a reconciliation of GAAP to non-GAAP financial measures.

In addition, CareFusion presents the non-GAAP financial measure “adjusted income from continuing operations per diluted share” on a forward-looking basis. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion's future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding CareFusion's financial condition and results of operations is included as Exhibit 99.3 to CareFusion's report on Form 8-K filed with the Securities and Exchange Commission on Feb. 2, 2012.

Cautions Concerning Forward-looking Statements

The CareFusion news release and the information contained herein contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. The matters discussed in these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business. The CareFusion news release and the information contained herein reflect management's views as of Feb. 2, 2012. Except to the limited extent required by applicable law, CareFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CAREFUSION CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Quarter Ended

Six Months Ended

December 31,

December 31,

(in millions, except per share amounts)

2011

2010

2011

2010

Revenue

$

915

$

886

$

1,759

$

1,697

Cost of Products Sold

458

441

875

839

Gross Margin

457

445

884

858

Selling, General and Administrative Expenses

267

270

540

542

Research and Development Expenses

40

36

79

76

Restructuring and Acquisition Integration Charges

7

17

14

39

Operating Income

143

122

251

201

Interest Expense and Other, Net

17

20

42

43

Income Before Income Tax

126

102

209

158

Provision for Income Tax

31

29

47

49

Income from Continuing Operations

95

73

162

109

Income from Discontinued Operations, Net of Tax

–

3

–

5

Net Income

$

95

$

76

$

162

$

114

Per Share Amounts: (1)

Basic Earnings per Common Share:

Continuing Operations

$

0.42

$

0.32

$

0.72

$

0.49

Discontinued Operations

$

–

$

0.01

$

–

$

0.02

Basic Earnings per Common Share

$

0.42

$

0.34

$

0.72

$

0.51

Diluted Earnings per Common Share:

Continuing Operations

$

0.42

$

0.32

$

0.72

$

0.49

Discontinued Operations

$

–

$

0.01

$

–

$

0.02

Diluted Earnings per Common Share

$

0.42

$

0.34

$

0.72

$

0.51

Weighted-Average Number of Common Shares Outstanding:

Basic

224.7

222.8

224.3

222.4

Diluted

226.6

224.5

226.5

224.2

(1)

Earnings per share calculations are performed separately for each component presented.  Therefore, the sum of the per share components from the table may not equal the per share amounts presented.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)

Quarter Ended December 31, 2011

Nonrecurring

(in millions, except per share amounts)

GAAP

Items (1)

Adjusted (2)

Revenue (3)

$

915

$

–

$

915

Cost of Products Sold

458

–

458

Gross Margin

457

–

457

Selling, General and Administrative Expenses

267

–

267

Research and Development Expenses

40

–

40

Restructuring and Acquisition Integration Charges

7

(7)

–

Operating Income

143

7

150

Interest Expense and Other, Net

17

–

17

Income Before Income Tax

126

7

133

Provision for Income Tax

31

3

34

Net Income

$

95

$

4

$

99

Per Share Amounts: (4)

Basic Earnings per Common Share

$

0.42

$

0.02

$

0.44

Diluted Earnings per Common Share

$

0.42

$

0.02

$

0.44

Weighted-Average Number of Common Shares Outstanding:

Basic

224.7

224.7

224.7

Diluted

226.6

226.6

226.6

Effective Tax Rate (5)

24.7%

27.0%

25.2%

____________

(1)

Reflects nonrecurring charges primarily related to restructuring.  

(2)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(3)

Revenues increased $29 million or 3% for the quarter ended December 31, 2011 compared to 2010, on a constant currency basis, the increase is also 3%.

(4)

Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

(5)

Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)

Six Months Ended December 31, 2011

Nonrecurring

(in millions, except per share amounts)

GAAP

Items (1)

Adjusted (2)

Revenue (3)

$

1,759

$

–

$

1,759

Cost of Products Sold

875

–

875

Gross Margin

884

–

884

Selling, General and Administrative Expenses

540

(4)

536

Research and Development Expenses

79

–

79

Restructuring and Acquisition Integration Charges

14

(14)

–

Operating Income

251

18

269

Interest Expense and Other, Net

42

–

42

Income Before Income Tax

209

18

227

Provision for Income Tax

47

5

52

Net Income

$

162

$

13

$

175

Per Share Amounts: (4)

Basic Earnings per Common Share

$

0.72

$

0.06

$

0.78

Diluted Earnings per Common Share

$

0.72

$

0.06

$

0.78

Weighted-Average Number of Common Shares Outstanding:

Basic

224.3

224.3

224.3

Diluted

226.5

226.5

226.5

Effective Tax Rate (5)

22.5%

26.1%

22.7%

____________

(1)

Reflects nonrecurring charges primarily related to nonrecurring restructuring charges and the spinoff.  

(2)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(3)

Revenues increased $62 million or 4% for the six months ended December 31, 2011 compared to 2010, on a constant currency basis, the increase is 3%.

(4)

Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

(5)

Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)

Quarter Ended December 31, 2010

Discontinued

Nonrecurring

(in millions, except per share amounts)

GAAP

Operations (1)

Items (2)

Adjusted (3)

Revenue

$

886

$

–

$

–

$

886

Cost of Products Sold

441

–

–

441

Gross Margin

445

–

–

445

Selling, General and Administrative Expenses

270

–

(11)

259

Research and Development Expenses

36

–

–

36

Restructuring and Acquisition Integration Charges

17

–

(17)

–

Operating Income

122

–

28

150

Interest Expense and Other, Net

20

–

–

20

Income Before Income Tax

102

–

28

130

Provision for Income Tax

29

–

6

35

Income from Continuing Operations

73

–

22

95

Income from Discontinued Operations, Net of Tax

3

(3)

–

–

–

Net Income

$

76

$

(3)

$

22

$

95

Per Share Amounts: (4)

Basic Earnings per Common Share

$

0.34

$

(0.01)

$

0.10

$

0.42

Diluted Earnings per Common Share

$

0.34

$

(0.01)

$

0.10

$

0.42

Weighted-Average Number of Common Shares Outstanding:

Basic

222.8

222.8

222.8

222.8

Diluted

224.5

224.5

224.5

224.5

Effective Tax Rate (5)

28.8%

n/a

20.3%

26.9%

____________

(1)

Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations.

(2)

Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  

(3)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(4)

Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

(5)

Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)

Six Months Ended December 31, 2010

Discontinued

Nonrecurring

(in millions, except per share amounts)

GAAP

Operations (1)

Items (2)

Adjusted (3)

Revenue

$

1,697

$

–

$

–

$

1,697

Cost of Products Sold

839

–

–

839

Gross Margin

858

–

–

858

Selling, General and Administrative Expenses

542

–

(28)

514

Research and Development Expenses

76

–

–

76

Restructuring and Acquisition Integration Charges

39

–

(39)

–

Operating Income

201

–

67

268

Interest Expense and Other, Net

43

–

–

43

Income Before Income Tax

158

–

67

225

Provision for Income Tax

49

–

17

66

Income from Continuing Operations

109

–

50

159

Income from Discontinued Operations, Net of Tax

5

(5)

–

–

Net Income

$

114

$

(5)

$

50

$

159

Per Share Amounts: (4)

Basic Earnings per Common Share

$

0.51

$

(0.02)

$

0.23

$

0.72

Diluted Earnings per Common Share

$

0.51

$

(0.02)

$

0.22

$

0.71

Weighted-Average Number of Common Shares Outstanding:

Basic

222.4

222.4

222.4

222.4

Diluted

224.2

224.2

224.2

224.2

Effective Tax Rate (5)

30.8%

n/a

24.7%

29.0%

____________

(1)

Reflects the impact of the divestiture of the International Surgical Products (ISP) business.  The ISP business was divested in April 2011, and has been classified as discontinued operations.

(2)

Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items.  

(3)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(4)

Earnings per share calculations are performed separately for each adjustment presented.  Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

(5)

Effective tax rate calculations are performed based on whole dollar amounts, and therefore may not equal the calculations based on amounts rounded in millions presented in the table above.

CAREFUSION CORPORATION

ADJUSTED SEGMENT FINANCIAL INFORMATION

(UNAUDITED)

Quarter Ended December 31, 2011

Nonrecurring

(in millions)

GAAP

Items (1)

Adjusted (2)

Medical Systems

Revenue

$

571

$

–

$

571

Segment Profit

$

121

$

3

$

124

Procedural Solutions

Revenue

$

344

$

–

$

344

Segment Profit

$

22

$

4

$

26

Six Months Ended December 31, 2011

Nonrecurring

(in millions)

GAAP

Items (3)

Adjusted (2)

Medical Systems

Revenue

$

1,080

$

–

$

1,080

Segment Profit

$

209

$

10

$

219

Procedural Solutions

Revenue

$

679

$

–

$

679

Segment Profit

$

42

$

8

$

50

Quarter Ended December 31, 2010

Nonrecurring

(in millions)

GAAP

Items (4)

Adjusted (2)

Medical Systems

Revenue

$

523

$

–

$

523

Segment Profit

$

95

$

16

$

111

Procedural Solutions

Revenue

$

363

$

–

$

363

Segment Profit

$

27

$

12

$

39

Six Months Ended December 31, 2010

Nonrecurring

(in millions)

GAAP

Items (4)

Adjusted (2)

Medical Systems

Revenue

$

991

$

–

$

991

Segment Profit

$

163

$

38

$

201

Procedural Solutions

Revenue

$

706

$

–

$

706

Segment Profit

$

38

$

29

$

67

____________

(1)

Reflects nonrecurring charges primarily related to restructuring.  

(2)

Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.

(3)

Reflects nonrecurring charges primarily related to nonrecurring restructuring charges and the spinoff.

(4)

Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.

CAREFUSION CORPORATION

SEGMENT AND SELECT BUSINESS LINE REVENUES

(UNAUDITED)

Quarter Ended

Six Months Ended

December 31,

December 31,

(in millions)

2011

2010 (1)

Percent

Change

2011

2010 (1)

Percent

Change

Medical Systems

Dispensing Technologies

$

257

$

229

12%

$

494

$

434

14%

Infusion Systems

239

223

7

445

415

7

Respiratory Technologies

69

65

6

129

130

(1)

Other

6

6

–

12

12

–

Total Medical Systems

$

571

$

523

9

$

1,080

$

991

9

Procedural Solutions

Infection Prevention

$

142

$

142

-%

$

280

$

277

1%

Medical Specialties

79

78

1

157

156

1

Specialty Disposables

65

73

(11)

131

143

(8)

Other

58

70

(17)

111

130

(15)

Total Procedural Solutions

$

344

$

363

(5)

$

679

$

706

(4)

Total CareFusion

$

915

$

886

3%

$

1,759

$

1,697

4%

____________

(1)

Previously reported GAAP amounts have been adjusted to reflect the impact of the divestiture of the International Surgical Products (ISP) business. The ISP business was divested in April 2011, and has been classified as discontinued operations.

(Logo:  http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)

Read the rest here:
CareFusion Reports Second Quarter Fiscal 2012 Results

www.youtube.com/watch?v=2qa6s2VGHIU

See the article here:
Medical Technologists Program – Video

Read more from the original source:
CONMED Corporation to Present at the 2012 Canaccord Genuity Musculoskeletal Conference

Wednesday, February 01 10:41:46

Over the last twelve months, medical technology companies publicly announced the investment of around E170m and the creation of an estimated 875 jobs, according to the Irish Medical Device Association (IMDA).

The figures come as the IMDA published its four year strategy (2012 -2015) for the med-tech sector today.

The 250 medical technology companies in Ireland, which consists of both domestic and FDI companies, export E7.2 billion worth of product annually and employ 25,000 people – the highest number of people working in the industry in any country in Europe, per head of population.

Recent reports published by IBEC show that during 2012 approximately half of all medical technology companies in Ireland expect to recruit additional employees and two thirds of medical technology companies expect turnover to increase during in the next five years.

The ongoing investment and job creation reflects the vibrancy of the medical technology sector in Ireland according to Paraic Curtis, Incoming Chairman of the IMDA.

“The investment of approximately E170m is across a wide range of development, manufacturing and R and D projects. In total these investments will create almost 875 jobs in the coming years. 2012 has also started brightly,” he said.

“The industry is poised for rapid convergence between technologies which will result in more collaboration and new products in the drug device and smart device development,” said Mr Curtis.

“In weathering the global economic downturn, the med-tech sector has become more productive, innovative and competitive, and will undoubtedly be a key driver of Ireland's export-led growth in coming years. Having said that, the next four years will not be without challenges with global healthcare expenditure coming under mounting pressure the challenge will be to demonstrate technologies which add value and efficiency. Given the industry's existing capacity to adapt, it is in a strong position to address these challenges,” he added.

Follow this link:
Med tech firms create 875 jobs in 2011

TORONTO–(BUSINESS WIRE)– According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, strong growth in the United States peripheral vascular (PV) market will come in lower-extremity indications, particularly through the adoption of drug-eluting stents (DES), which will be introduced into the US market in 2012.

DES has shown success in coronary indications, which has encouraged the development of DES products for peripheral vessels as well. While growing in popularity in Europe, peripheral versions of DES have not been available in the United States. Cook Medical’s Zilver PTX is expected to receive Food and Drug Administration (FDA) approval early in 2012. DES will mostly be used initially in femoropopliteal (fem-pop) indications, with use also in the infropopliteal in 2015 and beyond. The overall fem-pop segment had a value of $290 million in 2011 and is expected to reach over $460 million by 2016, a growth rate that averages nearly 10 percent per year.

Drug-eluting stents are expected to address some of the concerns with current stents used in lower-extremity indications, which include restenosis, high rates of re-intervention and durability concerns. The results should be better outcomes in safety and efficacy. As a result, DES in the fem-pop segment should reach 30,000 procedures per year by 2016, making up nearly 7.5 percent of all fem-pop stenting procedures.

“DES is promising, but improvements are constantly being made to its competitors, primarily bare-metal stents, but also including covered stents,” said MRG Analyst Fareed Hameed. “Flexible Stenting Solutions and IDEV technologies have new bare-metal designs, while W. L. Gore and Atrium Medical both have made continuous improvements to their covered stents. Physicians need to learn new procedures to use any of these designs effectively, which does decrease the speed of adoption.”

Millennium Research Group’s US Markets for Peripheral Vascular Devices 2012 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for PV stents, PTA balloon catheters, atherectomy devices, EPDs, aortic stent grafts, synthetic and biologic surgical stent grafts and PV accessory devices sold in the United States.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

See the original post:
Strongest Growth in US Peripheral Vascular Market to Come in Lower Extremity Indications

PLEASANTON, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) — ZELTIQ(R) Aesthetics, Inc. (Nasdaq:ZLTQ – News), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that Gordie Nye, Chief Executive Officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference in New York City.

Event: Leerink Swann 2012 Global Healthcare Conference
Date: Thursday, February 16, 2012
Time: 8 a.m. ET

An audio webcast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's website at www.coolsculpting.com. A replay of the presentation will be available for 30 days.

About ZELTIQ Aesthetics

ZELTIQ Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

Read this article:
ZELTIQ Aesthetics, Inc. to Present at the Leerink Swann 2012 Global Healthcare Conference

Read the original here:
Irish Medical Device Association: Vibrant Med Tech Sector in Ireland Identifies Continued Evolution & Convergence in 4 …

www.youtube.com/watch?v=zwEKw_DW1-A

Link:
Emergency Medical Technology: Paramedic, AAS – Video

Read the original post:
Dutch company turns cremation remains into global charity

View post:
AdVoice: Extreme Medicine's Biomask: Healing Combat's Worst Wounds

Log in to manage your products and services from The New York Times and the International Herald Tribune.

Don't have an account yet?
Create an account »

In order to access our Web site, your Web browser must accept cookies from NYTimes.com. More information »

E-Mail or Member ID

Password

Forgot Password?

Remember Me Log In

Read more from the original source:
Technology and Doctors

www.youtube.com/watch?v=SZt_JRFfiPY

See the article here:
Medical Devices